Health Condition 1: C679- Malignant neoplasm of bladder, unspecified
Conditions
Interventions
Intervention1: Intravesical sequential instillation of injection Gemcitabine and Docetaxel: Injection Gemcitabine 1g + Docetaxel 40mg sequential intravesical administration each drug to be retained f
Sponsors
GMC Jammu
Eligibility
Inclusion criteria
Inclusion criteria: Patients with histopathology reported non muscle invasive bladder cancer falling under category of intermediate and high risk NMIBC as per AUA Guidelines will be included in the study group. Patients will be included only after valid informed written consent for the study Adult patients above 18 yr and less than or equal to 80 years will be included. Both male and female patients will be included.
Exclusion criteria
Exclusion criteria: Patients not giving consent to be the part of study. Patients with muscle invasive bladder cancer. Pregnant and lactating females. Age less than 18 years or more than 80 years.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence-free survival at 24 monthsTimepoint: Base line assessment with Cystoscopy at initiation of therapy followed by Cystoscopy at 3rd month, 6th month 9th month, 12th month, 15th month, 18th month, and 24th month. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events & Patient-reported QoL scoresTimepoint: Patients will be assessed at the time of drug administration & on followup basis at 3rd month, 6th month, 9th month, 12th month, 15th month, 18th month, 21st month & 24th month. | — |
Countries
India
Contacts
Public ContactVineet Bhardwaj
Superspeciality Hospital Government Medical College Jammu.
Outcome results
None listed